7-OH: Effects, Risks, and Legal Status

7-hydroxymitragynine, or 7-OH, is an active alkaloid associated with kratom that binds to mu-opioid receptors. It occurs naturally in kratom leaf in trace quantities, while concentrated, converted, or synthetically enhanced 7-OH products can deliver exposures that are not comparable to traditional leaf preparations.

The U.S. Food and Drug Administration has not approved 7-OH as a prescription drug, over-the-counter drug, dietary supplement ingredient, or food additive. Products sold as tablets, gummies, shots, drink mixes, or powders do not become proven medicines because their labels use terms such as natural, botanical, focus, relief, or wellness.

What is 7-hydroxymitragynine?

7-hydroxymitragynine is a psychoactive kratom alkaloid with opioid-receptor activity. The compound is also called 7-OH, 7-hydroxy, or 7-HMG. It is chemically related to mitragynine, the predominant alkaloid in kratom leaf and kratom products, but the two compounds are not interchangeable names.

Kratom leaf contains only trace quantities of naturally occurring 7-OH. Mitragynine can also convert into 7-OH through metabolism or chemical processing, so a manufactured product may contain substantially more 7-OH than an unenhanced leaf preparation.

How do concentrated 7-OH products differ from kratom leaf?

Concentrated 7-OH products isolate, enrich, or manufacture the alkaloid to create exposure levels that differ from naturally occurring trace amounts in kratom leaf. A package labeled kratom does not establish whether its contents are leaf powder, an extract, a converted alkaloid product, or a formulation fortified with 7-OH.

This distinction changes the risk assessment. Traditional leaf, concentrated kratom extract, and isolated 7-OH differ in composition, potency, onset, and dose predictability; one product's serving size cannot be applied reliably to another product.

What forms does 7-OH come in?

Retail 7-OH appears in tablets, capsules, gummies, powders, shots, drink mixes, and products presented as kratom extracts. FDA warning letters have addressed firms marketing concentrated 7-OH in several of these forms, including products promoted for pain, mood, opioid withdrawal, or substance-use treatment.

Color, flavor, package size, and brand language do not identify alkaloid concentration. A laboratory certificate supplied by a seller also requires careful interpretation because the result applies only to the tested sample and does not establish clinical safety or FDA approval.

What effects does 7-OH produce?

7-OH activates mu-opioid receptors and can produce pain relief, euphoria, sedation, and other opioid-like effects. The response depends on product composition, amount, route, tolerance, metabolism, and exposure to alcohol, opioids, benzodiazepines, sedatives, or other drugs.

• Desired effects reported by users: relaxation, reduced pain, mood change, or relief of withdrawal discomfort.
• Common adverse effects: nausea, vomiting, constipation, dizziness, drowsiness, itching, sweating, or impaired coordination.
• Serious effects: profound sedation, confusion, seizure, loss of consciousness, or impaired breathing, particularly when other substances are involved.

These effects do not establish a safe dose. Concentration can differ across products, and a person cannot determine purity, potency, or contaminants from packaging or appearance.

What are the health risks of 7-OH?

7-OH carries risks associated with potent opioid-receptor activity, uncertain product composition, repeated exposure, and drug interactions. FDA communications identify addiction, tolerance, physical dependence, withdrawal symptoms, seizures, and respiratory depression among the concerns associated with concentrated 7-OH products.

Combining 7-OH with alcohol, opioids, benzodiazepines, sleep medications, gabapentinoids, or other central nervous system depressants compounds sedation and breathing risk. Stimulants do not cancel opioid effects and can add cardiovascular or neurologic stress.

Can 7-OH cause dependence or withdrawal?

Repeated 7-OH exposure can produce tolerance, physical dependence, withdrawal, and a pattern of compulsive use. Tolerance means a person needs greater exposure to obtain a previous effect; physical dependence means abrupt reduction can trigger symptoms; addiction describes impaired control and continued use despite harm.

Reported withdrawal features include craving, restlessness, anxiety, irritability, insomnia, sweating, muscle aches, gastrointestinal distress, and a return of symptoms the person was attempting to suppress. Symptom severity reflects the product's concentration, frequency and duration of use, other substances, medical conditions, and psychiatric status.

When craving, withdrawal, dose escalation, failed attempts to stop, or continued use despite harm establishes a treatment need, a kratom dependence and 7-OH treatment program can assess withdrawal risk, co-occurring substance use, mental health symptoms, and the appropriate level of care.

What signs require emergency medical care?

Unresponsiveness, slow or stopped breathing, blue or gray lips, seizure, collapse, severe confusion, or chest symptoms require emergency care. Call 911, place the person on their side if breathing, and provide rescue breathing or CPR when trained and indicated.

Give naloxone when opioid exposure is known or possible. Naloxone is appropriate for suspected opioid poisoning, but a response does not identify which opioid-receptor substance was involved; continued monitoring and emergency evaluation remain necessary because product contents and duration are uncertain.

Does a standard drug test detect 7-OH?

Routine workplace and clinical drug panels generally do not include a dedicated 7-OH assay. Specialized laboratory methods can identify mitragynine, 7-OH, or their metabolites when the ordered test includes those analytes.

A negative routine panel does not exclude 7-OH exposure, and a positive targeted result does not independently diagnose intoxication, impairment, dependence, or addiction. Interpretation requires the specimen type, collection time, laboratory method, cutoff, medication history, and clinical findings.

Is 7-OH legal in the United States?

Federal status is changing, and the legal answer depends on the substance, concentration, jurisdiction, and effective date of a final rule. On July 1, 2026, the Drug Enforcement Administration announced that it had started a temporary-scheduling process for 7-OH above a proposed threshold and certain synthetic derivatives.

Starting a scheduling process is not the same as a final scheduling action taking effect. New Jersey kratom and 7-OH law distinguishes enacted requirements from proposed restrictions and treats concentrated products separately where the law does. FDA approval and controlled-substance status remain separate questions; the absence of an effective scheduling rule would not make a product FDA-approved, lawfully marketed, or medically proven.

Is 7-OH approved to treat pain or opioid withdrawal?

The FDA has not approved 7-OH to treat pain, opioid withdrawal, opioid use disorder, anxiety, depression, or any other condition. Marketing language and consumer reports do not replace controlled clinical evidence, standardized manufacturing, dosing instructions, interaction review, or post-market safety oversight.

A person using 7-OH to manage pain, withdrawal, or psychiatric symptoms should receive a clinical assessment for the underlying condition and the product exposure. Abrupt self-directed changes can be hazardous when other opioids, alcohol, benzodiazepines, or medical conditions are involved.

Frequently asked questions about 7-OH

Is 7-OH the same as kratom?

No. 7-OH is one active alkaloid associated with kratom, while kratom leaf contains a mixture of alkaloids dominated by mitragynine. Concentrated or synthetically enhanced 7-OH products therefore should not be treated as equivalent to unenhanced leaf.

Is 7-OH an opioid?

7-OH is an opioid-receptor agonist because it activates mu-opioid receptors, although it is not a traditional opium-derived drug. The pharmacologic description explains opioid-like effects and risks; it does not establish pharmaceutical approval or product consistency.

Can one 7-OH product be stronger than another?

Yes. Products can differ in labeled amount, actual concentration, formulation, serving size, conversion method, and other ingredients. Those differences prevent a reliable potency comparison based only on package format or the word kratom.

Can 7-OH be used safely with prescription medication?

No combination should be assumed safe without review by a qualified clinician or pharmacist. Opioids, benzodiazepines, alcohol, sleep medications, gabapentinoids, antidepressants, and other drugs can change sedation, breathing, seizure, serotonin, or cardiovascular risk.

Does withdrawal prove that someone has an addiction?

No. Withdrawal demonstrates physiological adaptation, while addiction requires a broader pattern of impaired control, craving, hazardous use, or continued use despite harm. A clinical assessment distinguishes physical dependence from a substance use disorder and determines whether medical withdrawal support is needed.